The thesis
channel-pullback is a disciplined "buy the dip, but only in an uptrend" strategy. It waits for a confirmed uptrend, then buys pullbacks to the lower regression channel or a volume-support level, and exits into strength at the upper channel or overhead resistance. The idea is to harvest the oscillation inside a rising channel rather than chase breakouts. Its universe is 24 large-cap US names spanning tech, financials, healthcare, staples, and energy, which gives it room to rotate without straying into illiquid territory.
Recent activity
The last two weeks show the mechanism working as designed. On 30 October and 5 November it accumulated AAPL (5 shares near $345–$346) and MSFT (3 shares near $522–$539) on weakness, then sold both back on 4 and 9 November into higher prices ($351–$352 for AAPL, $546–$558 for MSFT) — textbook round-trips to the top of the channel. On 4 November it also added an energy tilt, buying XOM (11 @ $168.81) and CVX (9 @ $216.40). Scheduled runs have been quiet and clean: zero rejected orders across every session from 2 to 9 November. Portfolio value has drifted in a narrow band, sitting at $9,883.91 with $6,205.16 in cash after the 9 November run — essentially flat to marginally soft over the window.
Backtest and validation
Over 451 days the strategy returned 7.62% (final equity $10,761.52, ~4.19% CAGR) with a Sharpe of 0.40 and a 14.83% max drawdown. It fired 137 trades at a low 39.39% win rate, so the edge comes from letting winners run to the upper channel while cutting losers — an asymmetric-payoff profile that is coherent with the thesis. Turnover is high at 2,311%, though fees were a trivial $137 and there was no FX cost.
The four-fold walk-forward is where the picture turns cautious. Three of four folds were positive, and fold 3 (Jul–Dec 2025) was excellent: +20.68% at a 3.86 Sharpe. But fold 2 (Jan–Jul 2025) lost 11.42% at a −1.70 Sharpe, and out-of-sample return averaged just 3.63% (0.74 Sharpe) — roughly half the full-sample figure. Crucially, with 7 trials behind it the deflated Sharpe ratio is 0.196 (PSR 0.702), so after correcting for selection the odds that the true Sharpe is positive are weak. Validation status: failed.
Strengths and risks
The strengths are real: a clear, explainable thesis, clean execution, controlled single-fold drawdowns outside the bad patch, and a payoff shape that matches its logic. The risks are equally real. The low win rate makes it sensitive to regime — fold 2 shows what happens when pullbacks keep going and the "uptrend" assumption breaks. The thin deflated Sharpe warns that the headline return may owe more to one strong fold than to a durable edge.
Verdict: a promising, well-behaved strategy that has not yet earned an unconditional green light. Keeping it live in small size to gather forward evidence is defensible; sizing it up before the out-of-sample Sharpe strengthens would not be.